Gennova Biopharmaceuticals, a leading pharmaceutical company, has introduced a paediatric pack named Hamsyl – Junior that contains a drug called pegaspargase. This pack has been specifically designed to treat rare blood cancer in children. Pegaspargase is an important chemotherapy medication that is given to patients with acute lymphoblastic leukaemia (ALL), a type of blood cancer that mainly affects children. The paediatric pack of pegaspargase, marketed as Hamsyl – Junior, will now be available in a 1500 IU pack, providing a convenient and effective treatment option for young patients. The pack is priced at ₹Rs 20,970, making it more accessible to patients and their families. Gennova Biopharmaceuticals aims to make a positive impact on the lives of children suffering from rare blood cancer through the introduction of this paediatric pack.